Accepted for Publication: June 1, 2011.
Published Online: August 8, 2011. doi:10.1001/archneurol.2011.183
Author Contributions: All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Jack, Trojanowski, Bernstein, and Weiner. Acquisition of data: Jack, Wiste, Trojanowski, Shaw, Bernstein, and Weiner. Analysis and interpretation of data: Jack, Vemuri, Wiste, Weigand, Aisen, Trojanowski, Petersen, and Knopman. Drafting of the manuscript: Jack and Trojanowski. Critical revision of the manuscript for important intellectual content: Jack, Vemuri, Wiste, Weigand, Aisen, Trojanowski, Shaw, Bernstein, Petersen, Weiner, and Knopman. Statistical analysis: Vemuri, Wiste, Weigand, and Trojanowski. Obtained funding: Jack, Trojanowski, and Weiner. Administrative, technical, and material support: Jack, Trojanowski, Shaw, and Weiner. Study supervision: Jack, Aisen, Trojanowski, and Bernstein.
Financial Disclosure: Dr Aisen serves on a scientific advisory board for NeuroPhage; serves as a consultant to Elan Corporation, Wyeth, Eisai Inc, Bristol-Myers Squibb, Eli Lilly and Company, NeuroPhage, Merck, Roche, Amgen, Abbott, Pfizer, Novartis, Bayer, Astellas, Dainippon, Biomarin, Solvay, Otsuka, Daiichi, AstraZeneca, Janssen, and Medivation Inc; receives research support from Pfizer and Baxter International Inc; and has received stock options from Medivation Inc and NeuroPhage. Dr Petersen reports serving as a consultant for Elan Pharmaceuticals and GE Healthcare and serving on data monitoring committees for Pfizer and Janssen Alzheimer Immunotherapy. Dr Weiner reports serving on the advisory boards of Elan/Wyeth, Novartis, Banner, Lilly, VACO, Biogen Idec, Araclon, and Pfizer. He serves as a consultant to Elan/Wyeth, Novartis, Forest, Ipsen, Daiichi Sankyo Inc, AstraZeneca, Araclon, Pfizer, TauRx Therapeutics, Bayer, Biogen Idec, Exonhit Therapeutics, Servier, and Synarc. He has received honoraria from the American Academy of Neurology, Ipsen, NeuroVigil Inc, and the Institut Català de Neurociències Aplicades. He receives research funding from Merck and Avid. He owns stock in Synarc and Elan. He serves on the editorial advisory board for Alzheimer's & Dementia and the Journal of Magnetic Resonance Imaging. Dr Knopman reports that he serves on a Data Safety Monitoring Board for Lilly Pharmaceuticals and is an investigator for clinical trials sponsored by Elan Pharmaceuticals, Forest Pharmaceuticals, and Baxter Healthcare. He is deputy editor of Neurology and receives compensation for editorial services.
Funding/Support: This work was support by the National Institutes of Health (grant AG11378) and the ADNI.
Additional Information: Data used in the preparation of this article were obtained from the ADNI database (http://adni.loni.ucla.edu). As such, the investigators within the ADNI contributed to the design and implementation of the ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at http://adni.loni.ucla.edu/wp-content/uploads/how_to_apply/ADNI_Authorship_List.pdf.
Additional Contributions: We thank Samantha Wille, BA, for preparing the manuscript.